Evaluating cardiovascular risk in chronic kidney disease patients: A biomarker approach

Abdul Halim Abdul Gafor, Rozita Mohd, Rizna Abdul Cader, Wei Yen Kong, Marlyn Mohamad, Shamsul Azhar Shah, Arbaiyah Bain, Norella C.T. Kong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients. This study aimed to determine the roles of CVD biomarkers in CKD patients. This was a case-control study which recruited consecutive patients with stage 2-4 CKD patients with and without CVD. Serum levels of highly-sensitive C reactive protein (hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were measured. Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited. Twenty three (37.1%) of them had CVD. Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05). Diabetic patients had 8 times (95% CI 1.25-51.77, p< 0.05) higher risk to develop CVD. CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m2 p<0.05) and a lower triglyceride levels (1.3 (1.1-1.7) vs 1.8 (1.4-2.3) mmol/L, p<0.05), compared to those without CVD. Fasting blood sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05). There were no differences in their mean serum levels of hs-CRP, CysC, ADMA and SDMA. Risk factors including age, diabetes mellitus, hypertension and renal functions were still the most important CVD risk factors in CKD patients.

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalSains Malaysiana
Volume47
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Chronic Renal Insufficiency
Biomarkers
Cardiovascular Diseases
Cystatin C
Protein C
C-Reactive Protein
Renal Hypertension
Serum
Case-Control Studies
Diabetes Mellitus
Morbidity
Mortality

Keywords

  • Asymmetrical dimetylarginine
  • Biomarker
  • Cardiovascular disease
  • Chronic kidney disease
  • Cystatin C

ASJC Scopus subject areas

  • General

Cite this

Evaluating cardiovascular risk in chronic kidney disease patients : A biomarker approach. / Abdul Gafor, Abdul Halim; Mohd, Rozita; Abdul Cader, Rizna; Kong, Wei Yen; Mohamad, Marlyn; Shah, Shamsul Azhar; Bain, Arbaiyah; Kong, Norella C.T.

In: Sains Malaysiana, Vol. 47, No. 1, 01.01.2018, p. 149-155.

Research output: Contribution to journalArticle

@article{aeec959f1a0945338b1b21ac5db74578,
title = "Evaluating cardiovascular risk in chronic kidney disease patients: A biomarker approach",
abstract = "Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients. This study aimed to determine the roles of CVD biomarkers in CKD patients. This was a case-control study which recruited consecutive patients with stage 2-4 CKD patients with and without CVD. Serum levels of highly-sensitive C reactive protein (hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were measured. Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited. Twenty three (37.1{\%}) of them had CVD. Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05). Diabetic patients had 8 times (95{\%} CI 1.25-51.77, p< 0.05) higher risk to develop CVD. CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m2 p<0.05) and a lower triglyceride levels (1.3 (1.1-1.7) vs 1.8 (1.4-2.3) mmol/L, p<0.05), compared to those without CVD. Fasting blood sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05). There were no differences in their mean serum levels of hs-CRP, CysC, ADMA and SDMA. Risk factors including age, diabetes mellitus, hypertension and renal functions were still the most important CVD risk factors in CKD patients.",
keywords = "Asymmetrical dimetylarginine, Biomarker, Cardiovascular disease, Chronic kidney disease, Cystatin C",
author = "{Abdul Gafor}, {Abdul Halim} and Rozita Mohd and {Abdul Cader}, Rizna and Kong, {Wei Yen} and Marlyn Mohamad and Shah, {Shamsul Azhar} and Arbaiyah Bain and Kong, {Norella C.T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.17576/jsm-2018-4701-18",
language = "English",
volume = "47",
pages = "149--155",
journal = "Sains Malaysiana",
issn = "0126-6039",
publisher = "Penerbit Universiti Kebangsaan Malaysia",
number = "1",

}

TY - JOUR

T1 - Evaluating cardiovascular risk in chronic kidney disease patients

T2 - A biomarker approach

AU - Abdul Gafor, Abdul Halim

AU - Mohd, Rozita

AU - Abdul Cader, Rizna

AU - Kong, Wei Yen

AU - Mohamad, Marlyn

AU - Shah, Shamsul Azhar

AU - Bain, Arbaiyah

AU - Kong, Norella C.T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients. This study aimed to determine the roles of CVD biomarkers in CKD patients. This was a case-control study which recruited consecutive patients with stage 2-4 CKD patients with and without CVD. Serum levels of highly-sensitive C reactive protein (hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were measured. Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited. Twenty three (37.1%) of them had CVD. Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05). Diabetic patients had 8 times (95% CI 1.25-51.77, p< 0.05) higher risk to develop CVD. CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m2 p<0.05) and a lower triglyceride levels (1.3 (1.1-1.7) vs 1.8 (1.4-2.3) mmol/L, p<0.05), compared to those without CVD. Fasting blood sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05). There were no differences in their mean serum levels of hs-CRP, CysC, ADMA and SDMA. Risk factors including age, diabetes mellitus, hypertension and renal functions were still the most important CVD risk factors in CKD patients.

AB - Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients. This study aimed to determine the roles of CVD biomarkers in CKD patients. This was a case-control study which recruited consecutive patients with stage 2-4 CKD patients with and without CVD. Serum levels of highly-sensitive C reactive protein (hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were measured. Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited. Twenty three (37.1%) of them had CVD. Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05). Diabetic patients had 8 times (95% CI 1.25-51.77, p< 0.05) higher risk to develop CVD. CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m2 p<0.05) and a lower triglyceride levels (1.3 (1.1-1.7) vs 1.8 (1.4-2.3) mmol/L, p<0.05), compared to those without CVD. Fasting blood sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05). There were no differences in their mean serum levels of hs-CRP, CysC, ADMA and SDMA. Risk factors including age, diabetes mellitus, hypertension and renal functions were still the most important CVD risk factors in CKD patients.

KW - Asymmetrical dimetylarginine

KW - Biomarker

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Cystatin C

UR - http://www.scopus.com/inward/record.url?scp=85041925043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041925043&partnerID=8YFLogxK

U2 - 10.17576/jsm-2018-4701-18

DO - 10.17576/jsm-2018-4701-18

M3 - Article

AN - SCOPUS:85041925043

VL - 47

SP - 149

EP - 155

JO - Sains Malaysiana

JF - Sains Malaysiana

SN - 0126-6039

IS - 1

ER -